The content on this site is intended for healthcare professionals only
Prof McVie provides an update on the p-medicine project, outlining its aims, activities, challenges, and achievements.
p-medicine is a 4-year Integrated Project co-funded under the European Community’s 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalised medicine for the benefit of the patient.
In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to create support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualised therapy.
Click here for all of ecancer's p-medicine content and coverage, from articles to e-modules.
Visit the project website here.
New classification for identifying HR myeloma based on cytogenetic abnormalities
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Overview of the management of HER2-low breast cancer patients
Spindle cell lesions of the breast
